The partnership aims to enable affordable access to insulin to diabetic patients globally.

India. Biocon Biologics Limited, a subsidiary of Biocon Ltd. has joined hands with the International Diabetes Federation as the first biosimilar insulins company to help increase affordable access to insulin worldwide and support the Core Mission initiative and activities. The partnership coincided with the centenary celebrations of the insulin discovery made by physician and scientist, Sir Frederick Banting.

With Diabetes increasing at an alarming rate across all age groups and social classes, the demand for insulin is increasing at a rapid rate, which has made diabetes management an expensive process. Even after 100 years of discovery of the life-saving drug, Insulin remains beyond the reach of close to half a billion people now living with diabetes. As a credible market player in Global Human Insulin market, Biocon Ltd. is committed to make therapies accessible and affordable to those who need them the most. The significant action taken by Biocon will be a major driving factor to move the dial on diabetes care.

On the partnership, Global Head of Market Access & Policy, Biocon Biologics, said, “We are delighted to partner with the International Diabetes Federation and contribute to a stronger global voice for people living with diabetes. Despite 100 years since its discovery, a key impediment to successful diabetes treatment with insulins is the lack of equitable access to affordable insulins. As a leading global insulins player, we have a shared vision of finding viable, long-term solutions to improve insulin access and affordability. This partnership with IDF will further propel these efforts to realize the company’s aspiration of reaching ‘one in five’ insulin-dependent people with diabetes globally. Given our extensive experience in providing affordable insulins globally, we believe we can contribute and support IDF in driving real policy and access actions that will transform lives and diabetes care.”

TechSci research said, “With the rising diabetics population, the cost of the most popular types of insulin has tripled over the past decade. The increasing geriatric population and advancing healthcare facilities for chronic disorders are further expected to fuel the demand for human insulin in the coming years. Increasing partnership strategies of the company and technological innovations in drug discovery might help to curb down the prices and fuel the growth of global human insulin market.”

According to TechSci research report on “Global Human Insulin Market By Indication (Type I Diabetes, Type II Diabetes), By Brand (Lantus, Humulin R, Novolin R, Humulin N, Exubera, Afrezza, Novolin N), By Route of Administration (Subcutaneous, Transdermal, Nasal, Intravenous, Oral and Others), By Type (Basal, Bolus, Pre-mixed, Biosimilar, Traditional), By Onset Time (Rapid acting, Short-acting, Intermediate acting, Long acting, Pre-Mixed, Inhaled, Ultra-long Acting), By Products (Insulin Pens, Insulin Pumps, Infusion System, Injections), By Region, Forecast & Opportunities, 2025”, Global human insulin market was valued at USD26.91 billion in 2019 is expected to grow at a steady CAGR of 8.01% during the forecast period. Growing geriatric population, increasing diabetic patients, rising prevalence of obesity, and increasing demand for human insulin analogs are contributing to the surging demand for human insulin market, globally. Now a days, diabetes is not only restricted to geriatric population, but it is also common among youth. Also, the technological advancements have eradicated human physical activities leading to obesity and diabetes disorders which is directly influencing the growth of the market. Cost effectiveness, reimbursement prices and strict regulatory requirements for approval of insulin can be considered as a major restraining factor for the market as everyone suffering from diabetes might not be able to afford insulin.

According to TechSci research report on “Asia Pacific Biosimilar Insulin Glargine & Lispro Market By End User (Type 1 Diabetes and Type 2 Diabetes), By Country (Japan, China, India, South Korea, Bangladesh, Pakistan), Competition, Forecast & Opportunities, 2024”, Biosimilar is a biological product which is similar to the reference product, already approved by authorities and marketed by companies other than the patent holder company. Insulin is a hormone produced by pancreatic cell which is responsible for absorption of glucose from the blood. Lack of insulin in the body causes diabetes. Insulin is available in different forms depending upon the sources such as animal derived, chemically synthesized or produced through recombinant technology. Insulin can be categorized as fast acting, immediate acting and long acting depending upon the absorption of insulin from the blood in the body.